ClinicalTrials.gg
TerminatedNCT03465709Updated Sep 16, 2020Results posted

Pegcetacoplan (APL-2) in Neovascular AMD

A Phase 1/2 interventional study of Pegcetacoplan in Neovascular Age-related Macular Degeneration, sponsored by Apellis Pharmaceuticals, Inc.. Terminated at 4 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Apellis concluded that sufficient data were collected to meet the study objectives.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
405th of 491
17 · median 55
Started
2018
with 29 others
Phase 1/2
61 of 645
7 open now
Registered
383rd of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 405th largest by enrollment of the 491 interventional ones that give a count, is one of 30 that started in 2018, is one of 61 in phase 1/2, and was the 383rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 60 years.
  2. Normal Luminance best corrected visual acuity (NL-BCVA) of 24 letters or better using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (20/320 Snellen equivalent).
  3. Clinical diagnosis of neovascular AMD with the following criteria met:

    1. Eligible for an injection of an anti-VEGF injection with macular fluid present at Day -28.
    2. Must have been treated with anti-VEGF in study eye for at least 6 months prior to joining the study.
    3. At least 6 months of intravitreal anti-VEGF therapy at intervals not greater than 8 weeks (± 7 days) for the past 2 injections in the eye that is selected to be the study eye.
  4. A (50%) reduction in excess macular fluid or macular thickness in the study eye at the discretion of the investigator between Screening Day -28 and Screening Day -14 as assessed by SD-OCT.
  5. Female subjects must be:

    1. Women of non- (WONCBP), or
    2. Women of child-bearing potential (WOCBP) with a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study and refrain from breastfeeding for the duration of the study.
  6. Males with female partners of child-bearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study.
  7. Willing and able to give and to comply with the study procedures and assessments

Exclusion criteria

Exclusion Criteria:

  1. Presence of other causes of choroidal neovascularization (CNV) including pathologic myopia (spherical equivalent ≥ -6 diopters), central serous chorioretinopathy, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis.
  2. History of vitrectomy to the study eye
  3. Presence of any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination (e.g. advanced cataract or corneal abnormalities).
  4. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.
  5. Any history of endophthalmitis.
  6. Trabeculectomy or aqueous shunt or valve in the study eye.
  7. Aphakia or absence of the posterior capsule. Note: previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 60 days prior to baseline.
  8. Any ophthalmic condition that may require surgery or medical intervention during the study period or, in the opinion of the Investigator, could compromise visual function during the study period (e.g. severe uncontrolled glaucoma, diabetic macular edema, ischemic optic neuropathy, retinal vasculopathies).
  9. Any to IVT injection including current ocular or periocular infection.
  10. Current treatment for active systemic or localized infection.
  11. Participation in any systemic experimental treatment or any other systemic new drug within 6 weeks or 5 half-lives of the active (whichever is longer) prior to the start of study treatment. Note: clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary
  12. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the 24- month treatment period unlikely, or would make the subject an unsafe study candidate.
  13. Any baseline laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the Investigator is clinically significant and not suitable for study participation.
  14. Known to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the in pegcetacoplan solution
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan Study Drug

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs) Including by Maximum Severity

    TEAEs were defined as those adverse events (AEs) that developed or worsened after the first dose of study drug, up to 30 days after the last dose. The severity of the TEAEs was classified as mild (asymptomatic/mild symptoms); moderate (minimal, local/non-invasive intervention indicated); severe (medically significant but not life-threatening); life-threatening or leading to death. The number of subjects experiencing 1 TEAE in each category is presented. A maximum of 7 injections of pegcetacoplan (per subject) and a maximum of 13 injections of anti-VEGF (per subject) were received during the study.

    Time frame: Day 1 up to end of study (up to 1 year).

Secondary outcomes

  1. Mean Change From Baseline in SD-OCT Central Subfield Thickness (CST) up to 12 Months

    The CST was measured using SD-OCT throughout the study and the mean change from baseline at each timepoint is presented for the study eye.

    Time frame: Day 1 up to Day 360 (12 months).

  2. Number of Subjects With Clinically Significant Change From Baseline in Physical Examination Findings, Vital Signs and Laboratory Parameters

    Physical examinations, vital signs and laboratory parameters were monitored throughout the study and any subjects showing a clinically significant change from baseline over the study period are presented.

    Time frame: Baseline (Screening or Day 1) up to end of study (up to 1 year).

07

Results

Posted Sep 16, 2020
Limitations and caveats
Exposure was shorter than expected as some subjects experienced intraocular inflammation in the study eye due to an identified impurity. The sponsor terminated the study early as sufficient data were collected to meet study objectives.

Participant flow

Male and female subjects aged at least 60 years with a clinical diagnosis of neovascular age-related macular degeneration in the study eye were recruited to this Phase 1b/2, open-label study at 3 study centers in the United States conducted from 14 February 2018 until the last subject last visit on 05 April 2019.

Participant flow — Overall Study
Milestone15 mg Pegcetacoplan
Started17
Completed0
Not completed17
Withdrew: Study/site terminated by sponsor14
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryNumber of Subjects Experiencing Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs) Including by Maximum Severity

TEAEs were defined as those adverse events (AEs) that developed or worsened after the first dose of study drug, up to 30 days after the last dose. The severity of the TEAEs was classified as mild (asymptomatic/mild symptoms); moderate (minimal, local/non-invasive intervention indicated); severe (medically significant but not life-threatening); life-threatening or leading to death. The number of subjects experiencing 1 TEAE in each category is presented. A maximum of 7 injections of pegcetacoplan (per subject) and a maximum of 13 injections of anti-VEGF (per subject) were received during the study.

Time frame:
Day 1 up to end of study (up to 1 year).
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs) Including by Maximum Severity
Participants15 mg Pegcetacoplan
Any TEAEs15
Ocular study eye TEAE14
Nonocular TEAE7
TEAE at least possibly related to study drug5
TEAE at least possibly related to injection8
Serious TEAEs4
TEAEs leading to study drug discontinuation1
TEAEs leading to death0
Maximum severity: mild6
Maximum severity: moderate6
Maximum severity: severe3
Maximum severity: life-threatening0
SecondaryMean Change From Baseline in SD-OCT Central Subfield Thickness (CST) up to 12 Months

The CST was measured using SD-OCT throughout the study and the mean change from baseline at each timepoint is presented for the study eye.

Time frame:
Day 1 up to Day 360 (12 months).
Reported as:
Mean · micrometers
Mean Change From Baseline in SD-OCT Central Subfield Thickness (CST) up to 12 Months
micrometers15 mg Pegcetacoplan
Day 3012.9 ± 39.06
Day 6016.1 ± 66.99
Day 9015.1 ± 57.44
Day 12031.6 ± 68.33
Day 15034.8 ± 90.50
Day 18048.3 ± 92.21
Day 21018.5 ± 66.06
Day 24034.1 ± 66.35
Day 27049.2 ± 58.76
Day 30022.2 ± 73.29
Day 330-0.7 ± 57.17
Day 360-10.5 ± 48.67
SecondaryNumber of Subjects With Clinically Significant Change From Baseline in Physical Examination Findings, Vital Signs and Laboratory Parameters

Physical examinations, vital signs and laboratory parameters were monitored throughout the study and any subjects showing a clinically significant change from baseline over the study period are presented.

Time frame:
Baseline (Screening or Day 1) up to end of study (up to 1 year).
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Change From Baseline in Physical Examination Findings, Vital Signs and Laboratory Parameters
Participants15 mg Pegcetacoplan
Physical examination findings2
Vital signs0
Laboratory parameters0

Adverse events

Collected over Day 1 up to end of study (up to 1 year).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
15 mg Pegcetacoplan: Ocular Study Eye0/17 (0%)3/17 (17.6%)13/17 (76.5%)
15 mg Pegcetacoplan: Ocular Fellow Eye0/17 (0%)0/17 (0%)3/17 (17.6%)
15 mg Pecgectacoplan: Non-ocular0/17 (0%)1/17 (5.9%)6/17 (35.3%)
Most frequent serious events
Most frequent serious events
Event15 mg Pegcetacoplan: Ocular Study Eye15 mg Pegcetacoplan: Ocular Fellow Eye15 mg Pecgectacoplan: Non-ocular
UveitisEye disorders2/170/170/17
Non-infectious endophthalmitisEye disorders1/170/170/17
HaemoptysisRespiratory, thoracic and mediastinal disorders0/170/171/17
Most frequent other events
Showing 10 of 30
Most frequent other events
Event15 mg Pegcetacoplan: Ocular Study Eye15 mg Pegcetacoplan: Ocular Fellow Eye15 mg Pecgectacoplan: Non-ocular
Intraocular pressure increasedInvestigations5/170/170/17
Conjunctival haemorrhageEye disorders3/170/170/17
UveitisEye disorders2/170/170/17
Vision blurredEye disorders2/170/170/17
Ocular hypertensionEye disorders2/170/170/17
PhotopsiaEye disorders2/170/170/17
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/170/172/17
Eye painEye disorders1/170/170/17
Posterior capsule opacificationEye disorders1/170/170/17
Visual acuity reducedEye disorders1/170/170/17

Baseline characteristics

The safety set included all subjects who received at least 1 dose of pegcetacoplan.

Age, Continuous
Age, Continuous(years)15 mg Pegcetacoplan
Mean77.2 ± 8.76
Sex: Female, Male
Sex: Female, Male(Participants)15 mg Pegcetacoplan
Female7
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)15 mg Pegcetacoplan
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)15 mg Pegcetacoplan
White16
Native Hawaiian or Other Pacific Islander1
08

Study locations

4 sites
  • Apellis Clinical Site
    Beverly Hills, California 90211, United States
  • Apellis Clinical Site
    Hagerstown, Maryland 21740, United States
  • Apellis Clinical Site
    Cleveland, Ohio 44122, United States
  • Apellis Clinical Site
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2019, 13 months.

Results were first posted in Sep 2020, 1 year 5 months after primary completion. A results delay was requested in Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 14, 2018
StartActual
Feb 14, 2018
Primary completionActual
Apr 5, 2019
CompletionActual
Apr 5, 2019
Results delay requested
Jul 21, 2020
Results first posted
Sep 16, 2020
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03465709
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Feb 14, 2018
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019
Results posted
Sep 16, 2020
Last update
Sep 16, 2020

Study contacts

Federico Grossi, MD, PhD
study director · Apellis Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion